Amgen Inc. (AMGN): Price and Financial Metrics
AMGN Price/Volume Stats
Current price | $260.93 | 52-week high | $296.67 |
Prev. close | $266.31 | 52-week low | $211.71 |
Day low | $259.67 | Volume | 941,574 |
Day high | $266.03 | Avg. volume | 2,438,518 |
50-day MA | $256.62 | Dividend yield | 3.15% |
200-day MA | $243.82 | Market Cap | 139.57B |
AMGN Stock Price Chart Interactive Chart >
AMGN POWR Grades
- Quality is the dimension where AMGN ranks best; there it ranks ahead of 97.46% of US stocks.
- The strongest trend for AMGN is in Growth, which has been heading up over the past 177 days.
- AMGN ranks lowest in Momentum; there it ranks in the 9th percentile.
AMGN Stock Summary
- With a market capitalization of $143,193,046,154, AMGEN INC has a greater market value than 98.76% of US stocks.
- AMGEN INC's stock had its IPO on January 1, 1986, making it an older stock than 93.16% of US equities in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 15.83 for AMGEN INC; that's greater than it is for 96.36% of US stocks.
- Stocks that are quantitatively similar to AMGN, based on their financial statements, market capitalization, and price volatility, are TXN, NFLX, BA, GILD, and SAP.
- AMGN's SEC filings can be seen here. And to visit AMGEN INC's official web site, go to www.amgen.com.
AMGN Valuation Summary
- AMGN's price/earnings ratio is 17.9; this is 32.96% lower than that of the median Healthcare stock.
- AMGN's price/earnings ratio has moved up 98.7 over the prior 243 months.
Below are key valuation metrics over time for AMGN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
AMGN | 2023-09-22 | 5.4 | 21.1 | 17.9 | 15.1 |
AMGN | 2023-09-21 | 5.4 | 21.3 | 18.1 | 15.2 |
AMGN | 2023-09-20 | 5.5 | 21.4 | 18.2 | 15.3 |
AMGN | 2023-09-19 | 5.3 | 20.8 | 17.7 | 15.0 |
AMGN | 2023-09-18 | 5.3 | 20.8 | 17.6 | 14.9 |
AMGN | 2023-09-15 | 5.2 | 20.6 | 17.5 | 14.8 |
AMGN Growth Metrics
- The 3 year revenue growth rate now stands at 10.8%.
- The 3 year net cashflow from operations growth rate now stands at -10.5%.
- Its 2 year revenue growth rate is now at 9.81%.

The table below shows AMGN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 26,323 | 9,721 | 6,552 |
2022-09-30 | 26,330 | 9,880 | 6,835 |
2022-06-30 | 26,384 | 9,320 | 6,576 |
2022-03-31 | 26,316 | 9,321 | 5,723 |
2021-12-31 | 25,979 | 9,261 | 5,893 |
2021-09-30 | 25,767 | 8,606 | 5,609 |
AMGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AMGN has a Quality Grade of A, ranking ahead of 98.04% of graded US stocks.
- AMGN's asset turnover comes in at 0.412 -- ranking 113th of 682 Pharmaceutical Products stocks.
- UTHR, NBY, and AERI are the stocks whose asset turnover ratios are most correlated with AMGN.
The table below shows AMGN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.412 | 0.754 | 0.169 |
2021-06-30 | 0.408 | 0.753 | 0.169 |
2021-03-31 | 0.395 | 0.756 | 0.196 |
2020-12-31 | 0.400 | 0.758 | 0.206 |
2020-09-30 | 0.398 | 0.767 | 0.220 |
2020-06-30 | 0.395 | 0.782 | 0.225 |
AMGN Price Target
For more insight on analysts targets of AMGN, see our AMGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $250.00 | Average Broker Recommendation | 1.78 (Moderate Buy) |
Amgen Inc. (AMGN) Company Bio
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. Amgen's Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology. (Source:Wikipedia)
Latest AMGN News From Around the Web
Below are the latest news stories about AMGEN INC that investors may wish to consider to help them evaluate AMGN as an investment opportunity.
Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Weren’t.Amgen was the best-performing stock in the Dow Jones Industrial Average in the third quarter, while Zions Bancorp, up 30%, was the top stock in the S&P 500. |
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug ApprovalsThe demand for obesity drugs is intense and is likely to only greatly increase going forward, since over 40% of Americans were obese in 2020. |
Amgen (AMGN) Outpaces Stock Market Gains: What You Should KnowIn the latest trading session, Amgen (AMGN) closed at $270.82, marking a +0.68% move from the previous day. |
The Anti-obesity Drug Market Is About to Get More CrowdedObesity is an epidemic that affects more than 40% of all American adults, and it's creating a feeding frenzy for investors. With the rise of... |
Amgen (AMGN) Stock Sinks As Market Gains: What You Should KnowIn the latest trading session, Amgen (AMGN) closed at $268.98, marking a -0.02% move from the previous day. |
AMGN Price Returns
1-mo | 1.64% |
3-mo | 16.45% |
6-mo | 4.82% |
1-year | 17.04% |
3-year | 16.87% |
5-year | 49.29% |
YTD | 1.99% |
2022 | 20.43% |
2021 | 0.87% |
2020 | -1.99% |
2019 | 27.60% |
2018 | 15.23% |
AMGN Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Continue Researching AMGN
Want to see what other sources are saying about Amgen Inc's financials and stock price? Try the links below:Amgen Inc (AMGN) Stock Price | Nasdaq
Amgen Inc (AMGN) Stock Quote, History and News - Yahoo Finance
Amgen Inc (AMGN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...